International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-1 doi: 10.5281/zenodo.13371592
Original Research Article
Endothelial dysfunction in type 2 diabetes mellitus compared to healthy subjects
Published
Jan. 29, 2025
Abstract

Background: Endothelial dysfunction serves as an early indicator of atherosclerosis, preceding structural changes. Its assessment offers insight into the preclinical phase of cardiovascular disease, particularly crucial in Type 2 Diabetes Mellitus (T2DM) due to its association with glycemic control and disease duration. Flow-mediated dilation (FMD), reliant on endothelial nitric oxide release in response to shear stress, reliably gauges endothelial function across various conditions. Aim of the Study: This study aimed to evaluate endothelial dysfunction in T2DM patients compared to age- and sex-matched healthy controls. Additionally, it sought to correlate the duration of diabetes with the prevalence of endothelial dysfunction and examine its association with atherosclerosis risk factors in T2DM. Methodology: Non-invasive assessment using high-resolution Duplex Doppler Ultrasound of the Brachial Artery was conducted on 50 T2DM cases with or without vascular complications and 20 healthy controls. FMD, calculated as percentage increase in brachial artery diameter with increased flow, was employed to quantify endothelial function. Results: Endothelial dysfunction was observed in 20% of diabetics but absent in controls. Mean FMD values were significantly lower in diabetics (8.38 ± 12.32%) compared to controls (17.12 ± 10.53%; p < 0.007). FMD decline was noted across diabetes durations (10 years: 3.50 ± 1.61%), though prevalence did not escalate with longer duration. Conclusion: T2DM patients exhibit significantly impaired endothelial function compared to healthy counterparts, as evidenced by reduced FMD. The prevalence of endothelial dysfunction did not correlate with diabetes duration but was associated with hypertension, family history of diabetes, and smoking. Early intervention targeting these risk factors and optimizing glycemic control may mitigate vascular complications in T2DM.

Recommended Articles
Loading Image...
Volume-6, Issue-1
Citations
999 Views
21 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved